Psoriasis Therapeutics Market By Drug Class (TNF-alpha Inhibitors, Interleukin Inhibitors, Others), By Type (Plaque Psoriasis, Psoriatic Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical): Global Opportunity Analysis and Industry Forecast, 2021-2031
Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal. This makes the skin build up into bumpy red patches covered with white scales. They can grow anywhere, but most appear on scalp, elbows, knees, and lower back. Psoriasis cannot pass from person to person. It does sometimes happen in members of the same family. Psoriasis usually appears in early adulthood. For most people, it affects just a few areas. In severe cases, it can cover large parts of the body. The patches can heal and then come back throughout a person's life. However, there are many treatments. Some slow the growth of new skin cells, and others relieve itching and dry skin. Doctor selects a treatment plan that is right for patient based on the size of rash, where it is on the body, age, overall health, and other things of patients. Common treatments include steroid creams, moisturizers for dry skin coal tar (a common treatment for scalp psoriasis available in lotions, creams, foams, shampoos, and bath solutions), vitamin D-based cream or ointments, and Retinoid creams.
Major factors that drive growth of the global psoriasis therapeutics market include increase in geriatric population, growth in prevalence of plaque and psoriatic arthritis, favorable reimbursement policies, and rise in prescription volume of biological products. In addition, rise in awareness among people regarding different treatments available in the market further propel the market growth. However, health risks posed, owing to medication along with high costs of therapies restrain growth of the psoriasis therapeutics market during the forecast period. Conversely, increase in development of new biologics and novel pipeline drugs and high growth potential in untapped emerging countries are anticipated to provide lucrative opportunities to the market players.
The psoriasis therapeutics market is segmented on the basis of drug class, type, route of administration, end user, and region. According to drug class, the market is categorized into TNF-alpha inhibitors, interleukin inhibitors, and others. Interleukin inhibitors further segmented by distribution channel, including hospital pharmacies, drug stores & retail pharmacies, and online providers. On the basis of type, it is divided into plaque psoriasis, psoriatic arthritis, and others. On the basis of route of administration, it is classified into oral, topical, and parenteral. Furthermore, regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc, Eli Lilly and Company, Johnson & Johnson (J&J), Leo Pharma A/S, Novan, Inc., Novartis AG, Pfizer Inc., and Viatris Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psoriasis therapeutics market analysis from 2021 to 2031 to identify the prevailing psoriasis therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the psoriasis therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global psoriasis therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Rest Of Asia-Pacific
Japan
China
India
Australia
South Korea
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
Abbvie Inc.
Amgen Inc.
Bausch Health Companies Inc.
Eli Lilly and Company
Johnson and Johnson
LEO Pharma
Novan Inc. (EPI Health LLC)
Novartis AG
Pfizer Inc.
Viatris Inc. (Mylan NV)
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook